Edison issues outlook on Quantum Genomics (ALQGC)

LONDON, July 13, 2018 (GLOBE NEWSWIRE) — Quantum Genomics is a biopharmaceutical company investigating brain aminopeptidase A inhibitors, a new class of drug, for the treatment of hypertension and heart failure. Its lead programme, firibastat (QGC001), is in a 250-patient Phase IIb study in hypertensive overweight patients with patient dosing expected to be completed by the end of 2018 and data in Q119. Another Phase IIb in 300 subjects enrolled within 24 hours after suffering acute myocardial infarction (AMI) is expected to launch by the end of 2018 with results due in H220.

We value Quantum Genomics at €207m or €18.45 per share. Quantum ended 2017 with €11.1m in cash and investments. In March, it announced an equity line of credit with Kepler Cheuvreux, which could raise €24m over three years in four tranches. The company believes the equity line would fund it through the end of 2020. We may revisit our valuation following additional data from the ongoing clinical trials.

Click here to view the full report.

All reports published by Edison are available to download free of charge from its website

About Edison: Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world-renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisers and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.

Edison is authorised and regulated by the Financial Conduct Authority.

Edison is not an adviser or broker-dealer and does not provide investment advice. Edison’s reports are not solicitations to buy or sell any securities.

For more information please contact Edison:

Maxim Jacobs, +1 646 653 7027
Nathaniel Calloway, +1 646 653 7036

Learn more at www.edisongroup.com and connect with Edison on: 
LinkedIn         https://www.linkedin.com/company/edison-investment-research
Twitter           www.twitter.com/Edison_Inv_Res
YouTube         www.youtube.com/edisonitv

Primary Logo

Leave a Comment